Dow Down0.18% Nasdaq Up0.39%

Jazz Pharmaceuticals Public Limited Company (JAZZ)

163.05 Up 0.13(0.08%) 3:59PM EDT
|After Hours : 163.07 Up 0.02 (0.01%) 4:20PM EDT
ProfileGet Profile for:
Jazz Pharmaceuticals Public Limited Company
Connaught House
Fourth Floor
Dublin, 4
Ireland - Map
Phone: 353 1 634 7800

Index Membership:N/A
Full Time Employees:830

Business Summary 

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Jazz Pharmaceuticals Public Limited Company

Corporate Governance 
Jazz Pharmaceuticals Public Limited Company’s ISS Governance QuickScore as of Sep 1, 2014 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 4; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Bruce C. Cozadd , 50
Co-Founder, Exec. Chairman and Chief Exec. Officer
Mr. Russell J. Cox , 51
Chief Operating Officer and Exec. VP
Ms. Suzanne Sawochka Hooper , 48
Exec. VP and Gen. Counsel
Ms. Kathryn E. Falberg , 53
Mr. Robert M. Myers , 50
Co-Founder and Consultant
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders